HERCULES, Calif. - Bio-Rad Laboratories, Inc. (NYSE:BIO) reported fourth-quarter results that fell short of analyst ...

Bio-Rad has entered a binding offer to purchase all equity interests in French biotech Stilla Technologies. According to ...

Full Year 2024 Results Key Financial Results Revenue: US$2.57b (down 3.9% from ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has entered into a binding offer to ...

Bio-Rad Laboratories is slashing 5% of its staff, including over 100 in its Bay Area hometown, amid struggles in the biotech ...

Reports Q4 revenue $667.5M, consensus $679.75M. Norman Schwartz, Bio-Rad’s (BIO) Chairman and CEO, commented: “Bio-Rad demonstrated ...

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through ...

Bio-Rad Laboratories' cost-cutting plans come as the company swung to a loss in the fourth quarter amid lower sales across its life-science segment. The company posted a net loss of $715.8 million, or ...

(RTTNews) - OncoCyte Corp. (OCX), a diagnostics technology ... to close around February 10. Bio-Rad will provide additional financial support for an upcoming clinical trial and commercialization ...

Highlights,Bio-Rad Laboratories (BIO) drives innovation in life sciences and clinical diagnostics with a diversified product ...

The renowned manufacturer and global supplier of clinical diagnostics and life science research products has a market capitalization of $9.57 billion. Bio-Rad’s earnings surpassed estimates in each of ...